Please ensure Javascript is enabled for purposes of website accessibility

Sanofi and GlaxoSmithKline Snag a $2.1 Billion Contract for Their Coronavirus Vaccine

By Brian Orelli, PhD - Jul 31, 2020 at 6:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.S. government is supporting development and manufacturing of the coronavirus vaccine in exchange for 100 million doses.

Sanofi (SNY -1.27%) and GlaxoSmithKline (GSK -0.64%) secured $2.1 billion from the U.S. government to help support development and manufacturing of their coronavirus vaccine to help prevent COVID-19.

The contract, which is part of Operation Warp Speed, calls for Sanofi and GlaxoSmithKline to deliver 100 million doses of the vaccine in exchange for the upfront financial help. The government also has an option to purchase an additional 500 million doses for an undisclosed amount -- assuming, of course, that the vaccine protects patients in clinical trials.

In addition to the supplying the U.S. government, Sanofi and GlaxoSmithKline noted that they're discussing potential sales to European countries with the EU Commission.

Hand holding a syringe that's being injected into a shoulder

Image source: Getty Images.

Sanofi and GlaxoSmithKline plan to start a phase 1/2 clinical trial in September. The protein-based vaccine is substantially behind mRNA vaccines from Moderna and BioNTech, which are in or close to phase 3 development. Unfortunately, protein-based vaccines are harder to design, and setting up the manufacturing process takes longer.

On the plus side, protein-based vaccines have a long history of working, while mRNA is a new, unproven technology. With more experience, Sanofi and GlaxoSmithKline may be able to get through early-stage studies quicker. The duo is shooting for starting a phase 3 study by the end of 2020, putting it less than five months behind the leaders.

Of course, Sanofi also has a hand in the mRNA vaccine race through its partnership with Translate Bio (TBIO). Unfortunately, going into the pandemic, Translate Bio wasn't as established as Moderna and BioNTech, so it's taken the biotech a bit longer to develop an mRNA vaccine candidate. Sanofi and Translate expect to start a phase 1 clinical trial by the end of the year.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$49.08 (-1.27%) $0.63
GSK Stock Quote
GSK
GSK
$40.31 (-0.64%) $0.26
Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
TBIO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.